Ryan Kelly

Ryan Kelly

Associate Director of Business Development @ Abveris

Recent posts by Ryan Kelly

2 min read

Staying Open for Science, COVID Response

By Ryan Kelly on 3/20/20 12:44 PM

Abveris, Inc. 

March 18, 2020

RE: Staying Open for Science, COVID Response

 

To Our Valued Customers & Partners,

The COVID outbreak has caused significant disruptions to the science community worldwide, and your ongoing antibody discovery projects shouldn’t cause additional stress. Abveris will remain open for business and continue to provide contract research services during the state of emergency even if a "shelter-in-place" order is called. 

Abveris has multiple ongoing projects that directly contribute to drug development efforts for underserved diseases and indications (including COVID-19 and multiple other viral agents). Our end-to-end antibody discovery services are fully operational and we’re accepting new hybridoma and B cell screening discovery projects. Are you delaying your discovery work because of COVID-related antigen production delays? We can help.

Schedule 15 minutes with us today to discuss your project.

We are closely monitoring communications from the Massachusetts State and Federal Governments regarding measures to prevent the spread of the virus. Abveris has implemented mandatory work-from-home policies for non-essential staff, and employee schedules have been adjusted to promote social distancing. 

We welcome you to lean on us during these turbulent times. As always, we look forward to supporting your science.

 

Sincerely,

Garren Hilow

CEO of Abveris

 

Adversity has the effect of eliciting talents,

which in prosperous circumstances would have lain dormant

- Horace

Topics: Insider Press Releases Service & Product Updates
1 min read

WEBINAR: Integrating Octet into Early Antibody Discovery Workflows

By Ryan Kelly on 1/8/20 3:14 PM

Date: January 29, 2019 at 10AM ET (7AM PT)

Please join FortéBio and Abveris for an exclusive webinar featuring Colby Souders, Chief Scientific Officer of Abveris, who will review ways to utilize Octet screening to streamline antibody discovery projects.

Attend our live webinar

Who should attend:

  • Antibody discovery scientists and researchers engaged in therapeutic drug discovery.
  • Anyone interested in learning more about leveraging high-throughput Octet screening analyses to advance research and development.

Overview:

Integrating Octet into Early Antibody Discovery Workflows

Colby Souders, Chief Scientific Officer, Abveris

As industry-wide advancements in antibody drug discovery continue to push toward larger panels of candidates for early-stage characterization, more efficient identification of lead molecules through enhanced screening resolution is required. Integrating instruments like the Octet into the overall characterization workflow enables reliable, high throughput selection of lead candidates more effectively than alternative traditional techniques. This presentation will highlight a few unique methods of Octet utilization as a replacement or supplemental tool for various antibody discovery protocols. Comparisons across platforms, including traditional ELISA, flow cytometry, SPR, and in vivo studies will be presented.

 

Attend our live webinar

Topics: Insider
1 min read

Streamlining I-O Therapeutic Antibody Discovery: An Interview with Tracey Mullen, COO of Abveris

By Ryan Kelly on 12/3/19 7:34 AM

Insights from industry: Tracey Mullen, Chief Operating Officer of Abveris

Visit News Medical today to view an interview with Tracey Mullen, Chief Operating Officer of Abveris, in the "Insights from Industry" interview series.

In the interview, Tracey gives an overview of immuno-oncology therapeutic antibodies in development, strategies for therapeutic antibody discovery, and applications for the Intellicyt iQue high-throughput flow cytometry platform in antibody discovery.

For more information on antibody discovery projects utilizing high-throughput flow cytometry, contact Abveris today!

VIEW THE INTERVIEW

1 min read

WEBINAR: High-Throughput Antibody Discovery Targeting Glycoproteins for Apoptosis Induction in Cancer

By Ryan Kelly on 11/12/19 8:15 AM

Date: December 4, 2019 at 11AM ET (8AM PT)

IMG_1616Please join Sartorius and Abveris for an exclusive webinar featuring Tracey Mullen, Chief Operating Officer of Abveris, who will review an antibody discovery campaign targeting a glycoprotein for induction of apoptosis. Methods for immunization, screening for lead antibody candidates and subsequent functional characterization through the use of the Intellicyt® iQue platform will be detailed.

Who should attend:

  • Antibody discovery scientists and researchers engaged in therapeutic drug discovery for oncology indications.
  • Anyone interested in learning more about leveraging high-throughput flow cytometry analysis to advance research and development.

Interested, but have a scheduling conflict? Click here to register and receive an on-demand link to watch later.

About the webinar:

The use of monoclonal antibody-based drugs has proven very successful to target and treat cancer with more than half of late-stage clinical trial antibodies carrying an oncology indication. By employing multiple final formats, unconjugated or conjugated antibodies capitalize on methods of cell killing spanning from direct targeting and inhibition of cell survival pathways to shuttling and delivery of cytotoxic drugs. Specific cell surface antigen recognition is paramount to the success of these drugs, necessitating high resolution early stage characterization of lead antibody drug candidates prior to preclinical development.

Major advancements in high-throughput flow cytometry have enabled more exquisite antibody discovery within the oncology field by providing thorough analysis of on-cell antigen specificity and function earlier in the drug discovery process. In this webinar, an antibody discovery campaign targeting a glycoprotein for induction of apoptosis will be reviewed. Methods for immunization, screening for lead antibody candidates and subsequent functional characterization through the use of the Intellicyt iQue platform will be detailed.

Topics: Insider Service & Product Updates

Now Hiring: Join Our Lab or Business Development Team

By Ryan Kelly on 10/19/19 1:59 PM

October 19, 2019 – Are you a team player looking for an exciting new challenge at a growing company? Visit our careers page today to learn about our open positions in our laboratory and business development teams.

Do you think you have the right attitude and the right experience to join our team, but the jobs we've posted don't look quite right for you? We welcome your application. Apply as an "antibody enthusiast" today!

Topics: Team Updates
1 min read

CSO of Abveris, Colby Souders, Ph.D., to Present at Discovery On Target 2019

By Ryan Kelly on 8/22/19 9:07 AM

August 22, 2019 – Boston, MA – Representatives from Abveris will attend the 17th Annual Discovery On Target Conference, September 16-19, 2019, in Boston, MA. Colby Souders, Chief Scientific Officer of Abveris, will serve as chairperson for the Antibody Engineering and Development Forum and present "Screening Tools for Early Prediction of Development and Clinical Success" at 3:40PM on Thursday, September 19. An abstract for the presentation is listed below.

Click here to schedule an appointment with the Abveris team during the conference.

Abstract: As industry-wide advancements in antibody drug discovery continue to push toward larger panels of candidates for early-stage characterization, more efficient identification of lead molecules through enhanced screening resolution is required. Integrating tools and methods into the overall characterization workflow enables reliable, high throughput selection of lead candidates more effectively than alternative traditional techniques. Comparisons across platforms, including traditional ELISA, flow cytometry, Octet and in vivo studies will be presented that provide enhanced prediction of downstream development and clinical success.

About Discovery On Target: The 17th Annual Discovery on Target (DOT), the industry’s preeminent event on novel drug targets and technologies, will convene over 1,300 drug discovery professionals in Boston, MA, on September 16-19, 2019. This event highlights advances in current and emerging “hot” targets and technologies, as well as target validation strategies for the discovery and development of novel therapeutic agents, ranging from biologics to small molecules.

Topics: Team Updates Conferences
3 min read

Meet the Team: Summer Interns

By Ryan Kelly on 7/9/19 10:30 AM

July 9, 2019 - Our team is comprised of creative, friendly, mission-focused antibody enthusiasts who take pride in discovery science. This summer, Abveris will be featuring all of our team members on our blog to showcase the personalities that make our team a community. Twice a week, tune in to learn more about members of our team and see what they do inside and outside of work.

 

Matthew Bartolucci - Business Development Intern

MattBartolocci

 

Q: What excites you about science?

A: Science allows for all our our greatest questions to be answered. With the world always changing and evolving, our science is the way that we are able to adapt as a society and prepare for the world ahead.

Q: What is your favorite fun fact?

A: Garren, our CEO, and I have both play/played college ultimate frisbee for Bentley University's Icehouse

Q: What do you do in your free time?

A: Hanging out with friends, playing ultimate frisbee, slow-pitch softball and basketball!

Q: What is the coolest thing you have done at Abveris or what is your favorite memory of working here?

A: I love the start-up culture! One minute, I am helping with our marketing tasks, and the next, I am helping others take out the garbage. Everyone pitches in and embraces the culture! 

 

Madeleine Carbonneau - Business Development Intern

 

MaddyCarbonneau

Q: What excites you about science?

A: There is still so much to discover! Every generation of scientists has the opportunity to make fantastic and revolutionary contributions.

Q: What is your favorite fun fact?

A: The national animal of Scotland is a unicorn.

Q: What do you do in your free time?

A: I like to run, drink coffee, and travel.

Q: What is the coolest thing you have done at Abveris or what is your favorite memory of working here?

A: The coolest thing I have done at Abveris is working on the back end of the website. It is really cool to see how different languages, programs, and software work together. Also, the people working at Abveris are all really great and committed to their work which makes working here all the more enjoyable.

 

Tadhg Daly - Lab Intern

 

TadhgDaley

Q: What excites you about science?

A: The pursuit of knowing more than I did yesterday

Q: What is your favorite fun fact?

A: Sloths can hold their breath longer than dolphins can.

Q: What do you do in your free time?

A: I like to collect retro video games and merchandise as well as play games with my friends.

Q: What is the coolest thing you have done at Abveris or what is your favorite memory of working here?

A: Assisting in protein purifications and being responsible for my own cell cultures for others to use in fusions

 

Kelly Rothenberger - Lab Intern

 

KellyRothenberger

Q: What excites you about science?

A: The possibility for discovering new concepts and that can help people in the future. Especially on the industry side, where creating exciting new things, (such as antibodies) can aid those who are using the new drug products to fight against different diseases. The exponential growth of the biotechnology industry is exciting and I cannot wait to see what I will be apart of in my future!

Q: What is your favorite fun fact?

A: When helium is cooled to almost absolute zero, it becomes a liquid, flowing against gravity and can start running up and over the lip of a glass container.

Q: What do you do in your free time?

A: I mostly enjoy to workout as often as I can, and I also horseback ride when possible.

Q: What is the coolest thing you have done at Abveris or what is your favorite memory of working here?

A: Watching my first fusion (done by Justin) on my 6th day of interning! I am so excited to make more memories!!

2 min read

Abveris Deploys the Berkeley Lights Beacon® Platform for Antibody Discovery

By Ryan Kelly on 6/17/19 7:48 AM

Click here to read the press release on Business Wire.

Canton, MA, June 17, 2019 - Abveris, Inc., a leader in contract research antibody discovery, today announced the deployment of the Berkeley Lights, Inc. Beacon® optofluidic platform for antibody discovery.

Concurrent with this announcement, Abveris will be launching a sister company, AbX Biologics, with an exclusive focus on therapeutic antibody discovery services. AbX Biologics will partner with biopharma companies to provide premium contract research capitalizing on a combination of proprietary in vivo technologies and the Beacon platform. The full AbX Biologics solution is expected to launch in 2020, with beta collaborations beginning Q3 2019. Abveris will continue to provide critical reagent antibody discovery and other antibody-related services.

“We are committed to integrating new and innovative technologies to our expanding suite of antibody discovery capabilities in an effort to continue providing premium services for our partners. We believe that the pioneering technology of the Beacon platform in combination with our own cutting-edge discovery expertise will enable us to deliver development-ready candidates in industry-leading timelines,” said Tracey Mullen, Chief Operating Officer of AbX Biologics and Abveris.

The Beacon platform provides accelerated single-cell screening and high-resolution analysis to identify and isolate antigen-specific antibody-secreting cells in a single day. AbX Biologics will leverage this groundbreaking technology in combination with its proprietary immunization and high-throughput characterization capabilities to provide a streamlined, best-in-class therapeutic antibody discovery offering to its growing customer base.

“We are delighted that Abveris and AbX Biologics have selected the Beacon Platform and our Antibody Discovery workflow for their therapeutic antibody discovery programs,” said Dr. Eric Hobbs, CEO of Berkeley Lights. “Berkeley Lights is driven to help companies accelerate the discovery of the best cells for their unique programs. We believe our work with AbX Biologics will help speed its antibody discovery efforts by screening more potential drug candidates faster, reducing the time from target to high value lead, and ultimately delivering new therapies to market faster.”

About Abveris: Abveris is a premium Boston-area contract research organization specializing in antibody discovery. Abveris partners with large and small biopharmaceutical companies to discover novel therapeutic products and critical reagent antibodies using diverse platforms, including the proprietary DiversimAbTM hyperimmune mouse technology and a variety of humanized mice. Additional information about Abveris is available at www.abveris.com

About Berkeley Lights: Berkeley Lights, Inc. (BLI) is a digital cell biology company that develops and commercializes workflows and processes for the biotechnology sector to accelerate the design, discovery, development, and delivery of cell-based products. By operating at the intersection of biology, technology and information, our workflows automate the manipulation, analysis and selection of individual cells, creating ultimate scalability and deep cell insights. BLI enables the rapid deployment of biology for the production of sustainable and scalable sources of food, therapies, and energy.

The Beacon platform is for Research Use Only. Not for use in diagnostic procedures.

Contact for Abveris:

Garren Hilow

contact@abverisantibody.com

781-562-1170

 

 

Topics: Press Releases Service & Product Updates
1 min read

Abveris and TetraGenetics announce antibody discovery collaboration

By Ryan Kelly on 6/4/19 8:01 AM

Click here to read the press release on Business Wire.

Canton, MA, June 4, 2019 - Abveris, Inc., a leader in contract research antibody discovery, today announced that it has entered into a multi-target agreement with TetraGenetics, Inc. a biopharmaceutical company developing novel antibody therapeutics for ion-channel mediated disorders. Under the terms of the agreement, the companies will leverage their proprietary technologies to discover antibodies against traditionally difficult ion channel targets chosen by TetraGenetics.

"We are pleased to be working with TetraGenetics to develop antibodies against some of the most elusive therapeutic targets," commented Garren Hilow, CEO of Abveris. "The combined benefits of our proprietary hyperimmune platform along with TetraGenetics' unique ion channel technology provide a significant competitive advantage for discovery of antibodies against this traditionally difficult target class.

For the collaboration, the TetraGenetics’ TetraExpress platform will be leveraged in combination with the proprietary antibody discovery capabilities of Abveris for the discovery of diverse panels of antibodies with therapeutic potential.

“As our newest antibody partner, Abveris brings unique technology and a reputation for excellent execution to our growing list of drug discovery programs,” said Doug Kahn, CEO of TetraGenetics.

About Abveris: Abveris is a Boston-area specialty antibody discovery contract research organization located in Canton, Massachusetts, USA. Abveris partners with large and small biopharmaceutical companies to discover novel therapeutic products and critical reagent antibodies using diverse platforms, including the proprietary DiversimAb™ hyperimmune mouse technology. Additional information about Abveris is available at www.abveris.com.

About TetraGenetics: TetraGenetics is focused on the discovery and development of first-in-class biologic medicines for autoimmune diseases, oncology and pain. The company has the leading drug discovery platform (TetraExpress™) for identifying antibodies targeting ion channels and other transmembrane proteins. TetraGenetics is actively building a proprietary drug pipeline and working collaboratively with major biotech companies for antibody drug discovery. For more information, please visit: www.tetragenetics.com.

 

Contact for Abveris:

Garren Hilow

contact@abverisantibody.com

781-562-1170

 

Contact for TetraGenetics:

Suzanne Gibbons-Neff

suzanne@sgnpr.com

203-858-1325

Topics: Press Releases
1 min read

Abveris to attend the PEGS Boston Protein Engineering Summit

By Ryan Kelly on 3/24/19 12:05 PM

Boston, MA - March 24, 2019 - Will you be at PEGS Boston this year? Come visit us in the exhibit hall at Booth #518. In addition to our exhibit, scientists from Abveris will be presenting two posters about our proprietary mouse technology and our anti-idiotype antibody discovery process.  See you there from April 8th - 12th.

About PEGS Boston:

PEGS: The Essential Protein Engineering Summit is the industry’s preeminent event that inspires innovative biotherapeutic protein drug development.

The PEGS Summit has celebrated record growth for ten consecutive years with over 2,600 industry professionals in attendance and is on track to set another new record this spring.

PEGS Boston 2019 will host more than 400 lectures, panels, tutorials and round-table discussions, along with 150+ exhibitors, and 300 research posters on display in the exhibit hall. The speaker lineup includes world-renowned experts, visionaries, and influencers from top pharma, biotech, academic, and government institutions.

Topics: Conferences

Featured